pISSN 1226-6051
eISSN 2508-786X

Table. 4.

Table. 4.

Risk of cardiovascular comorbidity by pharmacotherapy group (vs non-pharmacotherapy group) in RA patients

Types of pharmacotherapyCV comorbiditiesOR (95% CI)
tDMARDIHD0.80 (0.76, 0.84)
CERI0.70 (0.65, 0.76)
HTN0.99 (0.96, 1.02)
DL1.64 (1.58, 1.69)
DM0.76 (0.73, 0.78)

Biologic agentIHD0.64 (0.61, 0.68)
CERI0.79 (0.73, 0.86)
HTN1.09 (1.06, 1.13)
DL1.42 (1.37, 1.47)
DM0.93 (0.90, 0.97)

RA: rheumatoid arthritis, CV: cardiovascular, tDMARD: traditional disease- modifying antirheumatic drugs, IHD: ischemic heart disease, CERI: cerebral infarction, HTN: hypertension, DL: dyslipidemia, DM: diabetes mellitus

Korean J Clin Pharm 2019;29:109-14 https://doi.org/10.24304/kjcp.2019.29.2.109
© 2019 Korean J Clin Pharm